Alnylam Pharmaceuticals Turns Profitable in Q4 2025

Got story updates? Submit your updates here. ›

Alnylam Pharmaceuticals (ALNY) has achieved a significant milestone, reporting full-year profitability in 2025 alongside strong fourth-quarter revenue exceeding $1.097 billion. This marks a pivotal moment for the company and potentially for the broader RNAi therapeutics field, signaling a shift from research-intensive losses to sustainable financial performance.

Why it matters

Alnylam's financial turnaround is a validation of its 'Alnylam 2030' strategy, which focuses on solidifying its leadership in ATTR (transthyretin) amyloidosis, driving long-term innovation, and achieving exceptional financial results. The company's success also highlights the potential of RNA interference (RNAi) therapeutics as a novel approach to treating diseases.

The details

Alnylam's revenue grew from $593.2 million in Q4 2024 to $1,097.0 million in Q4 2025, demonstrating accelerating momentum. Net income reached $186.4 million in the fourth quarter, contributing to a full-year net income of $313.7 million. The company's success is underpinned by its 'Alnylam 2030' strategy, which includes a $250 million investment to expand U.S. manufacturing capacity and enzymatic ligation capabilities.

• Alnylam reported full-year profitability in 2025.
• Alnylam's revenue grew from $593.2 million in Q4 2024 to $1,097.0 million in Q4 2025.
• Alnylam's net income reached $186.4 million in the fourth quarter of 2025, contributing to a full-year net income of $313.7 million.

What’s next

Alnylam has a robust pipeline with several key milestones expected in 2026, including four clinical readouts, three ongoing pivotal studies, three Phase 2 study initiations, and the filing of three or more new Investigational New Drug (IND) applications.